Profitability Recovery on Test — Can Sammaan Deliver ₹1,400 Cr FY27 PAT?
Q2 will be the critical test of management credibility after aggressive FY27 PAT and ROA guidance. Strong disbursement momentum (₹6,000 Cr in Q2, up 55% QoQ) is confirmed, but Street wants to see PAT inflection and evidence that the IHC-backed transformation is yielding profitability, not just loan growth.
The Setup
Sammaan Capital (formerly Indiabulls Housing Finance) has promised a comeback. The company reported a ₹7,598 Cr loss in FY26, but after IHC Capital invested ₹8,850 Cr for 43.5% control, management guided for ₹1,400 Cr PAT in FY27 and a 1.8% Return on Assets. Q1 FY27 delivered ₹243 Cr PAT, and October's business update showed ₹6,000 Cr disbursements in Q2—up 55% from Q1's ₹3,875 Cr. The numbers suggest momentum, but the Street wants to see sustainable profit margins, not just loan growth. Q2 results on Nov 14 will be the first real test of whether the transformation narrative holds.
What to Expect: The Key Metrics
~₹6,000 Cr
Confirmed in Oct 5 business update; 55% QoQ growth signals execution on track
~₹59,000–₹60,000 Cr
Q1 ended at ₹56,239 Cr; sequential growth ~4–5% on plan
₹300–₹500 Cr
Q1 delivered ₹243 Cr; on-track guidance requires ₹350+ Cr per quarter for ₹1,400 Cr FY27 goal
~1.6–1.8% annualized
Management targets 1.8% for FY27; validate improvement from historically negative returns
What a strong print looks like: PAT exceeds ₹350 Cr (pacing well toward ₹1,400 Cr FY27 target), asset quality remains stable (Net NPA What a weak print looks like: PAT misses expectations (below ₹300 Cr), cost-to-income ratio deteriorates, or management signals any delay in reaching the ₹1,400 Cr PAT milestone. Margin compression is the swing factor—high loan growth can hide weak profitability if yields fall faster than costs decline.
What the Street Says
Since Last Quarter: Corporate Actions & Filings
Oct 5
Q2 Business Update: ₹6,000 Cr disbursements
Validates operational momentum; guides expectations for PAT scaling
Oct 30
Warrant conversion allotment: 8.69 Cr shares to promoter Avenir at ₹139
Dilutes existing shareholders; monitoring capital structure & stake changes
Nov 4
Avenir divests 6.94% stake (8.69 Cr shares) post-allotment
Promoter reduced from ~35% to ~28% FY27 Q1; mixed signal on conviction
Sep 7 & Aug 31
NCD issuances: ₹750 Cr + ₹775 Cr in two tranches
Debt capital raising supports disbursement growth; leverage to monitor
Sep 25
NCLT admits second motion petition for amalgamation scheme
Long-term strategic consolidation; no immediate P&L impact but flag execution timeline
Routine corporate actions: Warrant allotment and follow-up divestment by promoter are procedural. Watch closely: NCD issuances imply rising leverage to fund growth. While debt capital is normal for NBFCs, a significant debt-to-equity spike or deteriorating profitability margins could signal stress. The NCLT amalgamation petition is in early stages and unlikely to be material for Q2, but if approved, could reshape the group's capital structure.
The Watch List: Three Things on Result Day
1 · PAT trajectory—is management on pace?
Q2 PAT must trend toward ₹350+ Cr to validate the ₹1,400 Cr FY27 target. Q1 delivered ₹243 Cr, implying Q2–Q4 must average ~₹386 Cr each. If Q2 comes in below ₹300 Cr or management downgrades FY27 PAT guidance, the multibagger thesis falters.
2 · Margin stability under scale
With disbursements up 55% QoQ, monitor cost-to-income ratio and net interest margin (NIM). Rapid growth can be illusory if margins compress. A widening cost ratio or NIM compression signals the PAT cannot scale with AUM growth.
3 · Asset quality—early signs of stress?
Fast origination can mask credit quality deterioration. Watch Q2 Net NPA (expect <1.5%) and any divergence in gross NPA or stage-2 asset migration. Any red flags here would derail investor confidence in the recovery thesis.
Sammaan Capital enters Q2 results with strong momentum narrative but unproven profitability. The IHC injection and 55% QoQ disbursement growth have attracted bullish analyst calls targeting ₹185–₹360 upside. However, negative ROE and modest margins mean the market is betting on a recovery, not celebrating a proven turnaround. Q2 results on Nov 14 will settle one key question: can the company translate scale into durable PAT? A credible print (₹350+ Cr PAT, stable margins, steady asset quality) validates the multibagger thesis. A miss or guidance cut likely triggers a re-rating compression back toward intrinsic value.
Sammaan Capital Q2 FY27: Flat Consolidated PAT Hides ~68% Adjusted Profit Decline
PAT +1.25% YoY · revenue -17.8% · margins expanding · inline vs street
₹1,849.97 Cr
-17.8% YoY
₹312.34 Cr
+1.25% YoY
16.88%
+3.2pp YoY
₹2.72
Sammaan Capital (formerly Indiabulls Housing Finance) reported consolidated PAT of ₹312.34 Cr for Q2 FY27, up just 1.3% YoY from ₹308.47 Cr and up 28.4% QoQ from ₹243.30 Cr, even as consolidated revenue from operations fell 17.8% YoY to ₹1,849.97 Cr (from ₹2,250.60 Cr) while rising 12.0% QoQ. The YoY PAT stability is misleading: stripping out the swing in the impairment line, pre-tax profit from core operations would have fallen roughly 68% YoY (an estimated ₹207.91 Cr versus ₹654.06 Cr a year ago, after tax ~₹152.9 Cr versus ~₹474.7 Cr) — this was a quarter kept in the black by a credit-cost reversal, not operating improvement.
Q2 FY-2027 vs prior quarters
Consolidated net profit margin expanded to 16.9% of total income from 13.65% YoY and 14.46% QoQ, but the expansion traces entirely to 'impairment on financial instruments (net of recoveries/written back)' swinging to a ₹216.66 Cr credit this quarter from a ₹229.03 Cr charge in Q2 FY26 — a ₹445.69 Cr favorable swing that offset the topline decline. That topline decline was itself driven by 'net gain on derecognition of financial instruments' collapsing to ₹7.19 Cr from ₹468.81 Cr a year ago, as last year's Identified-Exposures reclassification/ARC-sale-linked income recognition normalized. Interest income also fell YoY, to ₹1,161.26 Cr from ₹1,449.02 Cr, despite the standalone loan book growing to ₹40,935.69 Cr (from ₹33,914.56 Cr at March-26) — a yield or asset-mix shift the filing does not itself explain.
The stock went into the print at ₹137.52, up 3.6% over the past month of trading.
For context: PAT has now risen for 2 consecutive quarters.
What the summary numbers don't show
Basic EPS ₹2.72 (consolidated) vs ₹2.13 last quarter and ₹3.79 a year ago — paid-up equity capital rose to ₹229.34 Cr from ₹162.70 Cr YoY on Avenir's preferential allotment/warrant conversions.
Management expects to become a full-suite NBFC post the IHC investment and the merger of Sammaan Finserve, aiming to expand product offerings to mid-market to low-income India. The company plans to rapidly expand its branch network and leverage its technology platform. Long-term targets include increasing leverage to 4
Against our pre-result preview (PAT ₹300–500 Cr, annualized ROA 1.6–1.8% expected), the quarter is in-line but at the bottom of the range: PAT of ₹312.34 Cr annualizes to an ROA of ~1.72% on ₹72,556.36 Cr of consolidated assets, inside the expected band, and disbursements (~₹6,000 Cr) and AUM (~₹59,000 Cr) both matched the company's own prior business update. But the preview framed this quarter as a test of whether PAT inflection was genuine rather than loan-growth- or accounting-driven — the impairment-reversal dependency argues it is not yet proven. Management gave no quarter-specific guidance in this filing or press release (only the procedural board-outcome letter was available); the Feb-2026 concall's targets — 4x–4.5x leverage by 2030, 100bps core-mortgage credit cost, ~270bps cost-of-funds reduction by March 2027 — are multi-year and not verifiable off a single quarter. Standalone PAT of ₹341.96 Cr (+24.1% YoY) diverges sharply from the consolidated +1.3% YoY print; the ₹29.62 Cr gap is fully explained by a net loss at the Group's nine subsidiaries and trust this quarter, so the core lending entity performed better than the group number suggests. Concurrently, Avenir Investment RSC sold a 6.94% stake even as it was separately allotted 8.68 Cr shares via warrant conversion, and the NCLT has fixed November 16, 2026 as the next hearing date for the Sammaan Finserve merger scheme.
W1
Credit-cost normalization: two straight quarters of impairment write-backs (₹240.47 Cr Q1, ₹216.66 Cr Q2 FY27) have supported profit — a reversal would expose the ~68% adjusted YoY profit decline.
W2
Cost of funds progress toward management's ~270bps reduction target by March 2027, contingent on the IHC investment process completing.
W3
Sammaan Finserve merger scheme: NCLT has fixed November 16, 2026 as the next hearing date.